Results 11 to 20 of about 2,554,026 (187)
Lowering Serum Urate With
Arthritis & Rheumatology, 2023 ObjectiveGout is associated with a higher risk of fracture; however, findings on the associations of hyperuricemia and urate‐lowering therapy (ULT) with the risk of fracture have been inconsistent. We examined whether lowering serum urate (SU) levels with ULT to a target level (i.e., <360 μmoles/liter) reduces the risk of fracture among individuals ...
Jie Wei +8 more
openaire +5 more sources
PLoS ONE, 2019 Because the serum uric acid level increases as the glomerular filtration rate (GFR) decreases, hyperuricemia is associated with chronic kidney disease (CKD).
Hee Jung Jeon, Jieun Oh, Dong Ho Shin
doaj +2 more sources
Should all people starting urate-lowering therapy for gout receive anti-inflammatory prophylaxis? [PDF]
Exploration of Musculoskeletal DiseasesCo-prescription of anti-inflammatory prophylaxis with colchicine, non-steroidal anti-inflammatory drugs (NSAIDs), or corticosteroids when initiating urate-lowering therapy (ULT) for gout is recommended in clinical guidelines to prevent ULT-induced flares
Edward Roddy +2 more
doaj +2 more sources
Urate-lowering drugs in the treatment of gout: The unknown about the known [PDF]
Научно-практическая ревматология, 2021 The main direction of drug therapy for gout and other diseases associated with hyperuricemia is the long-term use of drugs aimed at correcting the level of uric acid.
T. S. Panevin +2 more
doaj +2 more sources
Factors associated with initiation and persistence of urate-lowering therapy [PDF]
Arthritis Research & Therapy, 2017 Gout is the most common inflammatory arthritic disease and is caused by crystal deposition secondary to persistent hyperuricemia. Etiological treatment with urate-lowering therapy (ULT) has been available since the 1950s but previous studies have demonstrated suboptimal degree of treatment.
Mats Dehlin +5 more
openaire +4 more sources
Kidney & Blood Pressure Research, 2018 Current urate-lowering therapy (ULT) includes three direct acting drugs (allopurinol, febuxostat, Rasburicase) and at least four ‘indirect’ drugs with other important targets (canagliflozin, losartan, fenofibrate and sevelamer).
Davide Viggiano +5 more
doaj +2 more sources
Effects of Discontinuation of Urate-Lowering Therapy: A Systematic Review [PDF]
Journal of General Internal Medicine, 2017 Urate-lowering therapy (ULT) is associated with low rates of adherence, leading to a potential risk of relapse of gouty arthritis, tophi, or urolithiasis. Our main aim was to identify the recurrence of gouty arthritis, tophi, or urolithiasis after discontinuation of ULT.
Beslon, Virginie +5 more
openaire +5 more sources
Personalized Medicine of Urate-Lowering Therapy for Gout [PDF]
, 2020 Gout is a common and complex form of arthritis that is characterised with hyperuricaemia. It is required urate-lowering therapy (ULT) for lifelong management. ULT includes decreasing uric acid product in serum, increasing renal urate excretion and promoting uric acid to allantoin for excretion.
Zhang, Y, Yan, D
openaire +3 more sources
Behavioral Characteristics of Gout Patients and Their Impact on the Results of Urate Lowering Therapy [PDF]
Acta Biomedica Scientifica, 2021 Background. Gout is frequently accompanied by hypertension, obesity, and/or impaired glucose tolerance, which are often complicated with heavy smoking and dietary violations, especially in male patients.Objective.
J. Chen +4 more
doaj +2 more sources
Prevention of arthritis attacks in the use of urate-lowering therapy in patients with gout [PDF]
Научно-практическая ревматология, 2019 During the first months after initiation of urate-lowering therapy in patients with gout, the risk of exacerbating arthritis substantially increases, frequently causing them to refuse this treatment.
M. N. Chikina
doaj +2 more sources